- May 15, 2013
- Posted by: Spotscreen
- Category: News
No Comments
A new drug treatment for basal cell carcinoma was recently trialed with encouraging results. The treatment, known as Dz13, targets the “c-jun” gene which is known to be responsible for triggering basal cell carcinoma – the most common type of skin cancer.
The drug treatment which was trialled on a human being, showed signs of reducing the tumor by getting the body’s natural immune system to start combating the tumor. Read More Here.